Safety and efficacy of apixaban versus warfarin in patients with end‐stage renal disease: Meta‐analysis

Overview of attention for article published in Pacing & Clinical Electrophysiology, April 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

twitter: 5 X users

guideline: 2 clinical guideline sources

Readers on

mendeley: 117 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 11,574 followers.

RT @Paul_Howard_IoW: In renal impairment: Apixaban is least affected and has been used in ESRF (though mostly for AF). Rivaroxaban and edo…

In renal impairment: Apixaban is least affected and has been used in ESRF (though mostly for AF). Rivaroxaban and edoxaban can be used in mild renal impairment, but see SPC for dose reductions https://t.co/5Nv1KYfRDA

In patients with advanced CKD and ESRD, the use of apixaban was associated with lower risk of major bleeding compared to warfarin, and was found to be relatively effective with no excess risk of thromboembolic events. https://t.co/XqZ3HSwpuc

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1 additional X posts.